Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Baseline ejection fraction ≥ 25% and ≤45% (as assessed by the site)~* NYHA class II or III (chronic, not transient, heart failure) despite receiving optimal medical therapy for heart failure~* Stable medication for heart failure for at least 30 days based on patient's medical records~* Baseline Peak VO2 ≥ 10 and ≤ 18.5 ml O2/Kg/min (as assessed by the site)~Exclusion Criteria:~* Potentially correctible cause of HF (valvular, congenital, or untreated ischemic heart disease)~* Clinically significant angina pectoris~* Hospitalization for HF requiring the use of inotropic support or IV diuretics within 30 days of enrollment~* PR interval greater than 375 ms~* Permanent or persistent atrial fibrillation/flutter or cardioversion within 30 days of enrollment.~* Exercise tolerance limited by condition other than heart failure (e.g., angina, chronic obstructive pulmonary disease (COPD), peripheral vascular disease, orthopedic or rheumatologic conditions) or unable to perform baseline stress testing~* Scheduled for a coronary artery bypass graft (CABG) or a percutaneous transluminal coronary angioplasty (PTCA) procedure, or CABG procedure within 90 days or a PTCA procedure within 30 days of enrollment.~* Biventricular pacing system, or indication for Biventricular pacing system~* Myocardial infarction within 90 days of enrollment.~* Mechanical tricuspid or aortic valves.~* Ventricular assist device~* Prior heart transplant~* Pregnant or planning to become pregnant during the study~* Age below 18~* Subject participating in another study, unrelated to CCM, at the same time (or within 30 days prior to enrollment to this study)~* Subjects on dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device implant (Type: OTHER): Patients randomized to the treatment group will receive optimal medical therapy for heart failure. and implantation of the OPTIMIZER System.
- Optimal medical therapy (Type: ACTIVE_COMPARATOR): Patients randomized to the control group will receive optimal medical therapy for heart failure.

Based on this trial design, predict the completion outcome and termination type (if applicable).